Elias, Marjanu Hikmah <br/><br/>
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.  [electronic resource] 

 -  Leukemia research  Apr 2014 
 - 454-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2013.12.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Asian People--genetics<br/>Benzamides--therapeutic use<br/>Catalytic Domain--genetics<br/>DNA Mutational Analysis<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Fusion Proteins, bcr-abl--chemistry<br/>Gene Frequency<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Malaysia--epidemiology<br/>Male<br/>Middle Aged<br/>Mutation, Missense<br/>Piperazines--therapeutic use<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Survival Analysis<br/>Young Adult